References
- Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheuma-toid arthritis. Arthritis Rheum. 2008;59:762–84.
- Steinbrocker 0, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc. 1949;140:659–62.
- Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum. 1992;35:498–502.
- Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose meth-otrexate. Ann Rheum Dis. 2003;62:686–7.
- Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still's disease. J Rheumatol. 2003;30:1624–5.
- Benucci M, Manfredi M, Mecocci L. Effect of etanercept plus lamivudine in a patient with rheumatoid arthritis and viral hep-atitis B. J Clin Rheumatol. 2008;14:245–6.
- Verhelst X, Orlent H, Colle I, Geerts A, de Vos M, van Vlier-berghe H. Subfulminant hepatitis B during treatment with ada-limumab in a patient with rheumatoid arthritis and chronic hepatitis B. Eur J Gastroenterol Hepatol. 2010;22:494–9.
- Kuwabara H, Fukuda A, Tsuda Y, Shibayama Y. Precore mutant hepatitis B virus-associated fulminant hepatitis during infliximab therapy for rheumatoid arthritis. Clin Rheumatol. 2010.
- Roux CH, Brocq 0, Breuil V, Albert C, Euller-Ziegler L. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spond-ylarthropathies with concurrent B or C chronic hepatitis. Rheu-matology (Oxford). 2006;45:1294–7.
- Carroll MB, Bond MI. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum. 2008;38:208–17.
- Kuroda T, Wada Y, Kobayashi D, Sato H, Murakami S, Nakano M, et al. Effect of etanercept and entecavil in a patient with rheumatoid arthritis who is a hepatitis B carrier: a review of the literature. Rheumatol Int. 2010.
- Robinson H, Walker-Bone K. Anti-TNF-alpha therapy for rheu-matoid arthritis among patients with chronic hepatitis B infection. Rheumatology (Oxford). 2009;48:448–50.
- Li S, Kaur PP, Chan V, Berney S. Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and ada-limumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients. Clin Rheumatol. 2009;28:787–91.
- Wendling D, Auge B, Bettinger D, Lohse A, Le Huede G, Bresson-Hadni S, et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis. 2005;64:788–9.
- Ogawa J, Harigai M, Akashi T, Nagasaka K, Suzuki F, Tominaga S, et al. Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving hu-manised anti-interleukin-6 receptor monoclonal antibody. Ann Rheum Dis. 2006;65:1667–9.
- Nagashima T, Minota S. Long-term tocilizumab therapy in a patient with rheumatoid arthritis and chronic hepatitis B. Rheu-matology (Oxford). 2008;47:1838–40.
- Galun E, Nahor 0, Eid A, Jurim 0, Rose-John S, Blum HE, et al. Human interleukin-6 facilitates hepatitis B virus infection in vitro and in vivo. Virology. 2000;270: 299–309.
- Wong VW, Yu J, Cheng AS, Wong GL, Chan HY, Chu ES, et al. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer. 2009;124:2766–70.